A Comparison of Manufacturing Processes for AIR OPTIX® COLORS Contact Lens
NCT ID: NCT01614678
Last Updated: 2017-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
49 participants
INTERVENTIONAL
2012-06-30
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Performance of AIR OPTIX® COLORS
NCT01338402
A Comparison of Silicone Hydrogel Contact Lenses: AIR OPTIX® COLORS Versus AIR OPTIX® AQUA
NCT01635920
Evaluation of the Cosmetic Performance of AIR OPTIX® COLORS
NCT01398787
AIR OPTIX® COLORS Registration Trial
NCT01440322
A Comparison of AIR OPTIX® COLORS Versus FRESHLOOK® COLORBLENDS
NCT01635933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DEVICE_FEASIBILITY
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto
Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
Lotrafilcon B contact lens with color, automated
Silicone hydrogel contact lens with color manufactured via an automated process
Lotrafilcon B contact lens with color, semi-automated
Silicone hydrogel contact lens with color manufactured via a semi-automated process
AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto
Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
Lotrafilcon B contact lens with color, automated
Silicone hydrogel contact lens with color manufactured via an automated process
Lotrafilcon B contact lens with color, semi-automated
Silicone hydrogel contact lens with color manufactured via a semi-automated process
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lotrafilcon B contact lens with color, automated
Silicone hydrogel contact lens with color manufactured via an automated process
Lotrafilcon B contact lens with color, semi-automated
Silicone hydrogel contact lens with color manufactured via a semi-automated process
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cylinder ≤ -0.75 diopter (D).
* Able to achieve visual acuity (VA) of at least 20/30 Snellen in each eye at distance with contact lenses (CLCVA) and best corrected visual acuity (BCVA) ≥ 20/25.
* Have spectacles that provide acceptable vision and be willing to wear them if unable to wear the study lenses.
* Successful daily wear of single-vision spherical soft contact lenses in both eyes during the past 3 months for a minimum of 8 hours/day, 5 days/week.
Exclusion Criteria
* Pre-existing ocular irritation that would preclude contact lens fitting.
* Currently enrolled in an ophthalmic clinical trial.
* Evidence of systemic or ocular abnormality, infection, or disease likely to affect successful wear of contact lenses or use of accessory solutions, as determined by the investigator.
* Pathologically dry eye.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CIBA VISION
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Holden Thomas, O.D.
Role: STUDY_DIRECTOR
Alcon Research
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-12-026
Identifier Type: OTHER
Identifier Source: secondary_id
P-383-C-005/C-12-026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.